GlassScriptPhysician profile
Amy K Scheeringa
NPI 1033369897
$3,968.29
in general payments reported to CMS, 2019-2025
19 companies · $1,318 in 2025
The $1,318 reported for 2025 was more than what 82% of Psychiatric/Mental Health (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $244).
See the full distribution for Psychiatric/Mental Health (Clinical Nurse Specialist)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $383 · 2022: $461 · 2023: $752 · 2024: $1,054 · 2025: $1,318.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,013 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,012.54 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $782.51 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Alkermes, INC. | $724.84 | 2022-2025 | Aristada, Lybalvi, Vivitrol |
| Axsome Therapeutics, INC. | $457.50 | 2022-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $348.79 | 2021-2025 | Rexulti, Abilify Asimtufii, Nuedexta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $272.33 | 2023-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $244.12 | 2021-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $241.02 | 2021-2024 | Invega Sustenna, Spravato |
| Lundbeck LLC | $211.17 | 2021-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Supernus Pharmaceuticals, INC. | $171.15 | 2023-2025 | Qelbree, Qelbree |
| Sunovion Pharmaceuticals INC. | $114.43 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $88.88 | 2022-2025 | Trintellix |
| Corium, LLC | $85.24 | 2022-2025 | Azstarys |
| Abbvie INC. | $80.26 | 2021-2023 | |
| Ironshore Pharmaceuticals INC. | $53.64 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $25.68 | 2024 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $21.19 | 2022 | |
| Eisai INC. | $16.69 | 2021 | |
| Idorsia Pharmaceuticals US INC | $15.75 | 2023 | Quviviq |
| Adlon Therapeutics L.P. | $13.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Scheeringa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.